Mdxhealth
Mdxhealth
0,81 %
1,240 EUR
0,01
Kurs
1,240
Hög
1,240
Förändring
0,81 %
Låg
1,240
Uppdaterad
09:10:28
Öppen
1,240
Factsheet for Mdxhealth
Company Profile
Description
MDxHealth SA is a multinational healthcare company. It develops and commercializes advanced epigenetic and other molecular tests to personalize the diagnosis and treatment of cancer. The firm's tests are based on proprietary genetic and epigenetic and other molecular technologies and assist physicians and the diagnosis of urologic cancers, the prognosis of recurrence risk and prediction of response to a specific therapy. Its product pipeline covers major cancer areas such as prostate, bladder, kidney, cervical and brain cancer. The company derives its revenues from the sale of clinical laboratory testing services, technology out-licensing deals, research and development service fees, and government grants. Geographically, it derives majority revenue from the United States of America.
Key Stats
Website: http://www.mdxhealth.com
Headquarter country: Belgium
Employees: 162
Market Cap (at close 19-07-2019): EUR 73M
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings
Forward Price/Earnings 26,10
Price/Free Cash Flow
Return on Assets -52,30 -19,50 -21,00 -32,60 -50,60
Return on Equity -67,80 -25,50 -27,20 -42,50 -63,20
Return on Invested Capital -66,70 -25,20 -26,80 -42,10 -63,20
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 28,40 40,51 29,97 17,64 11,67
Gross Profit 0,02 0,03 0,02 0,01 0,01
Gross Margin % 58,97% 74,81% 66,29% 60,86% 44,71%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -29,00 -10,00 -11,00 -14,00 -15,00
Net income -32,00 -12,00 -13,00 -14,00 -15,00
Basic Earnings Per Share -0,56 -0,25 -0,29 -0,35 -0,44
Operating Income -0,03 -0,01 -0,01 -0,01 -0,02
Operating Margin % -113,03% -30,30% -42,86% -81,53% -131,45%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -29,00 -10,00 -17,00 -14,00 -19,00
Capital Expenditures -1,00 -5,00 -5,00 -2,00 -1,00
Free Cash Flow -30,00 -15,00 -21,00 -16,00 -20,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 47,86 39,32 51,49 44,65 28,11 27,62
Long Term Assets 17,61 19,21 16,23 13,10 2,84 1,76
Total Assets 65,48 58,52 67,72 57,74 30,95 29,38
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 11,48 13,12 12,59 10,83 7,09 4,85
Long Term Liabilities 2,39 2,66
Total Liabilities 14,98 13,48
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -143,54 -111,09 -98,80 -85,63 -71,15 -55,82
Treasury Stock
Total Stockholder Equity 52,12 43,55 52,74 44,26 23,78 24,54
Net Tangible Assets 36,58 26,91 38,77 33,09 21,77 23,56